Table 1 Protocol for Active Surveillance as outlined by NICE: prostate cancer: diagnosis and treatment (CG175)
Timing | Tests |
|---|---|
At enrolment in active surveillance | Multiparametric MRI if not previously performed |
Year 1 of active surveillance | Every 3–4 months: measure PSA |
Throughout active surveillance: monitor PSA kinetics | |
Every 6–12 months: DRE | |
At 12 months prostate rebiopsy | |
Years 2–4 of active surveillance | Every 3–6 months: measure PSA |
Throughout active surveillance: monitor PSA kinetics | |
Every 6–12 months: DRE | |
Year 5 and every year thereafter until active surveillance ends | Every 6 months: measure PSA |
Throughout active surveillance: monitor PSA kinetics | |
Every 12 months: DRE |